Literature DB >> 18207124

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Aiyin Chen1, Lalitha Prajna, Muthiah Srinivasan, Rajendran Mahalakshmi, John P Whitcher, Stephen McLeod, Thomas M Lietman, Nisha R Acharya.   

Abstract

PURPOSE: To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility.
DESIGN: Retrospective, ancillary study using data and samples from a completed randomized clinical trial.
METHODS: Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics.
RESULTS: MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P=.01). MIC was not associated with three-month BSCVA (P=.71) or time to epithelialization (P=.35).
CONCLUSIONS: MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207124      PMCID: PMC2267868          DOI: 10.1016/j.ajo.2007.11.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.

Authors:  C N Baker; S A Stocker; D H Culver; C Thornsberry
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Corneal ulceration in the developing world--a silent epidemic.

Authors:  J P Whitcher; M Srinivasan
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 3.  Review of clinical experience with microbial keratitis associated with contact lenses.

Authors:  K R Wilhelmus
Journal:  CLAO J       Date:  1987 Jul-Aug

4.  Predictive value of susceptibility tests for the outcome of antibacterial therapy.

Authors:  V Lorian; L Burns
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

Review 5.  Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).

Authors:  Barry A Schlech; Eduardo Alfonso
Journal:  Surv Ophthalmol       Date:  2005-11       Impact factor: 6.048

Review 6.  In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Authors:  David W Stroman; Joseph J Dajcs; Gale A Cupp; Barry A Schlech
Journal:  Surv Ophthalmol       Date:  2005-11       Impact factor: 6.048

7.  In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance.

Authors:  D Greenwood
Journal:  J Infect Dis       Date:  1981-10       Impact factor: 5.226

8.  Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.

Authors:  Kirk R Wilhelmus; Robert L Abshire; Barry A Schlech
Journal:  Arch Ophthalmol       Date:  2003-09

9.  Incidence of ulcerative keratitis in a defined population from 1950 through 1988.

Authors:  J C Erie; M P Nevitt; D O Hodge; D J Ballard
Journal:  Arch Ophthalmol       Date:  1993-12

10.  The importance of initial management in the treatment of severe infectious corneal ulcers.

Authors:  S D McLeod; L D LaBree; R Tayyanipour; C W Flowers; P P Lee; P J McDonnell
Journal:  Ophthalmology       Date:  1995-12       Impact factor: 12.079

View more
  17 in total

1.  Orlans HO, Hornby SJ, Bowler IC (2011) In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10-year review. Eye Jan 21 [Epub ahead of print] PMID 21252952.

Authors:  Stephen Kaye; Rose Gilbert; Henri Sueke; Timothy Neal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-29       Impact factor: 3.117

2.  Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Authors:  Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2012-03-23       Impact factor: 9.079

3.  The steroids for corneal ulcers trial: study design and baseline characteristics.

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

4.  Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Authors:  Muthiah Srinivasan; Jeena Mascarenhas; Revathi Rajaraman; Meenakshi Ravindran; Prajna Lalitha; David V Glidden; Kathryn J Ray; Kevin C Hong; Catherine E Oldenburg; Salena M Lee; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-10-10

5.  Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.

Authors:  Robert E Fintelmann; Eliza N Hoskins; Thomas M Lietman; Jeremy D Keenan; Bruce D Gaynor; Vicky Cevallos; Nisha R Acharya
Journal:  Arch Ophthalmol       Date:  2011-04

6.  Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Authors:  Prajna Lalitha; N Venkatesh Prajna; Catherine E Oldenburg; Muthiah Srinivasan; Tiruvengada Krishnan; Jeena Mascarenhas; C M Vaitilingam; Stephen D McLeod; Michael E Zegans; Travis C Porco; Nisha R Acharya; Thomas M Lietman
Journal:  Cornea       Date:  2012-06       Impact factor: 2.651

7.  Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.

Authors:  Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Palanisamy Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Natalie Nardone; Kathryn J Ray; David V Glidden; Nisha R Acharya; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-28       Impact factor: 4.799

8.  Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.

Authors:  Kathryn J Ray; Lalitha Prajna; Muthiah Srinivasan; Manoharan Geetha; Rajarathinam Karpagam; David Glidden; Catherine E Oldenburg; Catherine Q Sun; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  JAMA Ophthalmol       Date:  2013-03       Impact factor: 7.389

9.  Nocardia keratitis: clinical course and effect of corticosteroids.

Authors:  Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Jeganathan Lakshmi Priya; Aileen Sy; Catherine E Oldenburg; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Thomas M Lietman; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2012-09-05       Impact factor: 5.258

10.  New treatments for bacterial keratitis.

Authors:  Raymond L M Wong; R A Gangwani; Lester W H Yu; Jimmy S M Lai
Journal:  J Ophthalmol       Date:  2012-09-06       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.